Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies
Behnood Bikdeli, Azita H. Talasaz, Farid Rashidi, Babak Sharif-Kashani, Mohsen Farrokhpour, Hooman Bakhshandeh, Seyed Hashem Sezavar, Ali Dabbagh, Mohammad Taghi Beigmohammadi, Pooya Payandemehr, Mahdi Yadollahzadeh, Taghi Riahi, Hossein Khalili, Sepehr Jamalkhani, Parisa Rezaeifar, Atefeh Abedini, Somayeh Lookzadeh, Shaghayegh Shahmirzaei, Ouria Tahamtan, Samira Matin, Ahmad Amin, Seyed Ehsan Parhizgar, David Jiménez, Aakriti Gupta, Mahesh V. Madhavan, Sahil A. Parikh, Manuel Monréal, Naser Hadavand, Alireza Hajighasemi, Majid Maleki, Saeed Sadeghian, Bahram Mohebbi, Gregory Piazza, Ajay J. Kirtane, Gregory Y.H. Lip, Harlan M. Krumholz, Samuel Z. Goldhaber, Parham Sadeghipour
Topics & Concepts
Critically illMedicineCoronavirus disease 2019 (COVID-19)PlaceboIntensive care medicine2019-20 coronavirus outbreakStatinInternal medicineAlternative medicineVirologyDiseaseOutbreakPathologyInfectious disease (medical specialty)COVID-19 Clinical Research StudiesHeparin-Induced Thrombocytopenia and ThrombosisVenous Thromboembolism Diagnosis and Management